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Abstract
Background: The provision of smoking cessation support in Australian drug and alcohol treatment services is
sub-optimal. This study examines the cost-effectiveness of an organisational change intervention to reduce smoking
amongst clients attending drug and alcohol treatment services.
Methods/design: A cluster-randomised controlled trial will be conducted with drug and alcohol treatment centres
as the unit of randomisation. Biochemically verified (carbon monoxide by breath analysis) client 7-day-point
prevalence of smoking cessation at 6 weeks will be the primary outcome measure. The study will be conducted in
33 drug and alcohol treatment services in four mainland states and territories of Australia: New South Wales, Australian
Capital Territory, Queensland, and South Australia. Eligible services are those with ongoing client contact and that
include pharmacotherapy services, withdrawal management services, residential rehabilitation, counselling services, and
case management services. Eligible clients are those aged over 16 years who are attending their first of a number of
expected visits, are self-reported current smokers, proficient in the English language, and do not have severe untreated
mental illness as identified by the service staff. Control services will continue to provide usual care to the clients.
Intervention group services will receive an organisational change intervention, including assistance in developing
smoke-free policies, nomination of champions, staff training and educational client and service resources, and free
nicotine replacement therapy in order to integrate smoking cessation support as part of usual client care.
Discussion: If effective, the organisational change intervention has clear potential for implementation as part of the
standard care in drug and alcohol treatment centres.
Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12615000204549. Registered on 3
March 2015.
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Background
In Australia, 77–95 % of people entering drug and alcohol
treatment smoke tobacco [1, 2]; this prevalence is five times
that of the general adult population (12.8 % in 2013) [3]. A
similar high prevalence of smoking has been reported in
US [4] and UK addiction treatment facilities [5, 6]. People
with substance use disorders report heavier nicotine de-
pendence and smoke more cigarettes per day than the gen-
eral population [2, 7, 8]. As a result, people seeking
treatment for substance use and substance dependence ex-
perience a greater tobacco-related burden of illness [9].
Studies show that clients treated for substance use and
dependence are very interested in quitting smoking and
can be successful in quitting [2, 10]. Large-scale trials
among alcohol-dependent patients show long-term
smoking cessation of 10–15 % among those receiving
counselling and pharmacotherapy [11–13]. Trials of pa-
tients on methadone maintenance programs also show
cessation during treatment ranging from 9 % to 33 %, al-
though with a high prevalence of relapse [14–16]. A re-
view of 24 studies showed that smoking cessation
intervention enhanced other drug treatment goals as
well [17]. A meta-analysis comparing the safety and effi-
cacy of quit interventions during and after addiction
treatment found short-term smoking cessation was com-
parable for participants during treatment and those in
sustained remission from substance use disorders [18].
Longer-term treatment benefits in the likelihood of ab-
stinence from alcohol and drugs were found when
smoking was addressed during, rather than after, treat-
ment [18]. These results suggest addressing smoking
with drug and alcohol clients does not impair treatment
and can improve other treatment outcomes.
Tobacco treatment guidelines in Australia [19] and
other countries [20, 21] recommend smokers with sub-
stance dependence be offered medication and counsel-
ling to assist quitting. Evidence-based approaches
include assessing smoking status, advising smokers to
quit, providing counselling/pharmacotherapy, consider-
ing treating substance abuse problems with medications
that target these problems but may also help with smok-
ing cessation (e.g., naltrexone with alcoholism), and fol-
low up on quit attempts.
Despite the benefits, studies have found that drug and
alcohol treatment centres do not routinely offer clients
support with smoking cessation [22, 23]. The decision
on whether they address client smoking is left to individ-
ual staff members within these centres [23–26]. Factors
within treatment settings that reduce the probability of
addressing client smoking include a lack of smoke-free
policies, staff smoking, a smoking-permissive culture
[24], and common beliefs that service users do not want
to quit or that quitting will negatively impact the treat-
ment [27].
The use of organisational change approaches to smok-
ing cessation in drug and alcohol treatment centres is
novel, and evaluations of its effectiveness in those set-
tings remain preliminary. Organisational changes for
smoking cessation involve (1) establishing systems for
identifying and recording smoking status; (2) providing
education, resources, and feedback to build the capacity
of staff to support quit attempts; (3) dedicating staff to
provide quit treatment; (4) implementing and promoting
organisational policies to provide quit services; and (5)
including effective smoking cessation support (both
counselling and pharmacotherapy) as part of usual care
[28]. Organisational change models also encourage the
‘denormalisation’ of smoking within the treatment envir-
onment. Small pilot studies suggest an organisational
change approach can successfully integrate smoking ces-
sation support into routine care provided by drug and
alcohol clinics [29–32]. For example, Guydish et al. [29]
report that 6 months following the introduction of the
‘Addressing Tobacco Through Organizational Change’
(ATTOC) model in three large treatment centres in the
US, staff attitudes towards smoking cessation treatment,
distribution of nicotine replacement therapy (NRT), and
staff provision of tobacco treatments became signifi-
cantly more positive. ATTOC included staff training in
the core component of organisational change, policy de-
velopment, leadership support, and access to NRT. The
next iteration of organisational change research for
smoking cessation needs to rigorously evaluate patient
outcomes and costs. The protocol has been written fol-
lowing the SPIRIT advice (see Additional file 1).
Study aims
The primary aim of the Tackling Nicotine Together
(TNT) trial is to determine the effectiveness of an or-
ganisational change intervention in increasing smoking
cessation (7-day-point prevalence of abstinence)
amongst clients attending drug and alcohol treatment
services. Secondary aims of the trial are to examine the
cost-effectiveness of the organisational change interven-
tion compared to usual care and to examine the effect-
iveness of an organisational change intervention in
increasing prolonged smoking abstinence, quit attempts,
and the use of cessation aids as well as reducing nicotine
dependence amongst clients attending drug and alcohol
treatment services. Changes in delivery of smoking ces-
sation care to clients will also be measured.
Hypotheses
1. Compared to clients in treatment centres allocated
to minimal ethical care (control group), clients
attending intervention services will have: (1) 9.5 %
higher smoking cessation rate at the 6-week follow-
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up as measured by biochemically verified 7-day-
point prevalence of abstinence (primary outcome
measure) and (2) 8.5 % higher prolonged abstinence
at the 6-month follow-up (secondary outcome
measure).
2. The organisational change intervention will be more
cost-effective than usual care at 6-month follow-up.
Methods/design
A cluster-randomised trial will be conducted with drug
and alcohol treatment services as the unit of randomisa-
tion. The primary outcome measure is biochemically
verified client 7-day-point prevalence of abstinence at
6 weeks. As full concealment of allocation is difficult in
behavioural cluster trials, this study will use partial
blinding, whereby randomisation of the clusters will be
performed by a biostatistician not involved with the
study and who will be blind to the identity of the treat-
ment centres. Similarly, follow-up assessments will be
conducted by interviewers blind to the experimental
condition. The flow chart of the TNT trial is displayed
in Fig. 1. Ethical approval for this study was obtained
from the Hunter New England Human Research Ethics
Committee (HREC), Australian Capital Territory Health
Fig. 1 Schematic of the Tackling Nicotine Together (TNT) trial study design. CATI, computer-assisted telephone interview
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HREC, South Australia Health HREC, and University of
Newcastle HREC.
Setting
The study will be conducted in 33 governmental and
non-governmental drug and alcohol treatment centres in
four mainland states or territories of Australia: New
South Wales (NSW), Australian Capital Territory
(ACT), Queensland (QLD), and South Australia (SA).
Recruitment and randomisation of treatment centres
Recruitment
Eligible drug and alcohol services were those providing
services involving face-to-face client sessions to a large
number of clients (minimum of 50 per year) in NSW,
Queensland, ACT and SA. Recruitment was conducted
through key contacts (such as Directors of Health Ser-
vices or peak non-governmental organisations) who
assisted in recruitment. Treatment services were invited
to participate by writing and followed up by telephone
and in person.
Randomisation
Randomisation was undertaken by an independent stat-
istician who used a combination of stratified and re-
stricted randomisation in Stata version 13 to ensure
equitable distribution across the intervention groups of
stratification factors including the state/territory (NSW,
Queensland, ACT, and South Australia), service type
(governmental or non-governmental organisation), and
smoking policy (partial or total smoking ban). Stratifica-
tion based on these factors produced ten non-zero
strata. Five strata included an even number of sites (24
in total), with these sites randomised within strata to ei-
ther the intervention or the usual care group. The five
remaining strata with an uneven number of sites were
combined to form two ‘meta’ strata, based on the state
(either ACT or QLD, each with n = 4 services) and
which were also homogeneous for the type of smoking
policy, and one single site strata. The PERCOM module
was then used to generate all the possible combinations
of treatment allocations within these two meta-strata
and restricted the set of all 36 combinations of treatment
allocations within strata 1 and strata 2 to be those with
balance of service type between treatment arms. One of
these 18 balanced allocations was then randomly se-
lected, and finally, the remaining single site was ran-
domly allocated using simple randomisation to either
intervention or usual care. This produced a final alloca-
tion sequence that, at most, had an imbalance of one site
for each stratification factor—the best that could be
achieved with an uneven number of sites. All random
sampling and treatment allocation was achieved by gen-
eration of random uniform values.
Participants
Treatment service clients eligible for inclusion in the
trial will be those aged over 16 years who are attending
their first of a number of visits (to allow for repeated ex-
posure to the intervention), who are self-reported
current smokers, sufficiently proficient in English, and
do not have severe untreated mental illness as identified
by treatment staff in order to give informed consent. In-
formed consent will be obtained from all participants.
Client recruitment
A staff member at each treatment centre will be trained
to conduct client recruitment. Baseline client recruit-
ment will occur over a minimum 6-month period. Eli-
gible clients will be provided with written information
about the study and, if interested in participating, asked
to complete the consent form and a baseline touchsc-
reen survey. Eligible clients will be informed that the
study aims to expand the services provided by the treat-
ment centre, it involves completing a survey about their
smoking, and their carer or case-worker may discuss
their smoking with them.
Data collection
Participants will be asked to complete a baseline survey
via a touchscreen tablet at the time of recruitment and
an additional two surveys over the telephone after
6 weeks and 6 months. At the 6-week and 6-month
follow-up assessments, allowing for a 2-week grace
period post-baseline, participants who report 7-day-
point prevalence of abstinence will also be asked to re-
turn to the service to provide a breath sample to meas-
ure carbon monoxide (CO).
Retention strategies
To maximise retention of the participating clients at the
6-week and 6-month follow-up, this study will employ a
number of evidence-based strategies [33, 34]. Follow-up
dates and times will be set during recruitment, and par-
ticipants will be provided with a TNT ‘business card’ fea-
turing all study contact details and the 6-week and 6-
month follow-up times. Detailed contact information
will be obtained from clients agreeing to participate, in-
cluding their current home address, phone numbers,
and email addresses. These contact details will also be
collected for a nominated family member or friend. On-
going contact with the participant via regular text mes-
sages, letters, or emails will be used to remind
participants to keep their contact details up-to-date with
the research team and to remind them when their
follow-up survey is coming up. Finally, clients will be of-
fered monetary reimbursement (AUD$50 grocery vou-
cher) when all assessments are completed at the 6-
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month follow-up for costs incurred (including travel
costs and child care).
Intervention and comparator
Control group
Treatment services in the control group will provide
usual care.
Intervention group
Intervention services will participate in an ‘organisa-
tional change’ intervention which aims to establish or
improve routine screening, assessment, and delivery of
smoking cessation care and treatment to clients. Organ-
isational changes integrate identifying smokers and offer-
ing cessation treatment into routine care. The main goal
of the intervention is to increase the level of evidence-
based brief smoking cessation advice, education, and
nicotine replacement therapy offered to clients as part of
their usual treatment.
The conceptual framework for the intervention is
based on organisational change literature that is tailored
to smoking cessation—Fiore et al.’s System Changes ap-
proach [20, 28] and Ziedonis’ ATTOC model [32]. The
organisational change strategies that will be used to help
build the treatment services capacity to deliver the
smoking cessation support to clients are outlined below.
1. Engaging organisational support. High-level support
for change within the organisation is crucial for
implementing change across an entire site [35]. Ad-
vocacy, staff meetings, and communications (e.g.
newsletters, noticeboards, and email) will be used to
sequentially engage all levels of staff and address staff
and systems barriers.
2. Identifying and supporting a smoking cessation
‘champion’. Having a key staff member who takes
the lead role in ensuring smoking cessation
treatment is provided to clients can improve
treatment delivery and compliance [28, 32]. During
training, one staff member in each treatment centre
will be nominated by the group to take a lead role.
That staff member will be assisted by other support
staff to deliver brief advice to clients who smoke,
oversee client survey recruitment, and follow up
client progress.
3. Promoting centre policies that support and provide
tobacco dependence services. Ensuring treatment
centres are smoke-free environments will address
the barrier of smoking-permissive social norms [36].
On a site-specific basis, project staff will assist with
implementing smoke-free policies, smoke-free sign-
age, support for staff to quit, and changes to pro-
cesses to create a cessation-supportive environment.
Services that have policies in place will be assisted in
developing programs to maximise enforcement.
Total smoke-free policies will be the goal.
4. Implementing a system of identifying smokers. The
goal of this strategy is to ensure that all patients are
asked about tobacco use as part of every clinical
encounter. Each TNT site will be asked to develop a
way for assessing and recording client smoking
status using their electronic or paper-based record
system. Such prompts have been shown to increase
the rate that clinicians intervene with smokers [37].
5. Providing education and resources (including staff
training). Training is necessary to ensure that staff
has the skills and information to assist their clients
in making a quit attempt [28, 32]. Staff will receive
training on smoking cessation techniques, focusing
on the 5As (ask, assess, advise, assist, and arrange
follow-up) and appropriate NRT provision in the
form of a 1-day face-to-face workshop with a cred-
ited smoking cessation trainer. It is designed to en-
courage and support smoking cessation practices as
part of routine care. The Stages of Change [10] the-
oretical model is used to assess a smoker’s motiv-
ation to quit and tailor support.
6. Providing case-worker and client feedback.
Computerised feedback has been found to improve
the delivery of preventive services in general practice
[38]. For the service, newsletters and brief update
reports will be used to motivate staff and keep the
service engaged with the intervention. In addition,
CO monitors will be used to provide motivational
feedback to clients regarding their progress during
quit attempts.
7. Providing evidence-based tobacco dependence
treatments (including NRT). Tobacco dependence
treatment is both clinically effective and cost-effective
[36]. Providing tobacco dependence treatment within
the treatment centre setting reduces the cost barriers
to cessation [39]. Existing resources such as QUIT-
line® referrals will be used where appropriate. Treat-
ment centres will be supplied with NRT free of cost
during client treatment. This intervention will provide
a flexible range of NRT options and extends the lim-
ited NRT subsidies currently available through the
Australian Pharmaceutical Benefits Scheme for pre-
scription nicotine patches only.
8. Planning for maintenance and follow-up.
Hospital-based research has found that a smoking
treatment summary in the discharge plan aids cessa-
tion maintenance [40]. The goal of this strategy is to
ensure that clients have a plan in place to maintain
cessation or to follow-up on quit interest and inten-
tions on discharge from the service. This may in-
clude sending smoking treatment summaries to the
client’s primary healthcare provider or linking the
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client with telephone follow-up services such as
Quitline.
Each intervention site will communicate regularly with
project staff to ensure that these intervention compo-
nents are implemented over a 12-week period (mini-
mum). A printed intervention manual (full version –
Additional file 2; brief version – Additional file 3) will
be provided to each intervention site.
Measurements
Primary outcome measure
The primary outcome measure is client smoking cessa-
tion at 6-week follow-up using biochemically verified 7-
day-point prevalence. The 7-day-point prevalence of ab-
stinence will be assessed using standard items to deter-
mine the proportion of participants who have not
smoked any tobacco in the preceding 7 days: ‘Have you
smoked a cigarette, even a puff in the last 7 days?’ [41].
Self-reported point-prevalence abstinence at 6 weeks will
be verified using measures of CO in expired air.
Secondary outcomes
Prolonged abstinence will be assessed using the Russell
Standard criteria [42]. The quit date will be determined
at the 6-week follow-up and confirmed at the 6-month
follow-up, while taking into account a 2-week grace
period. Additional secondary outcomes to be collected
at client 6-week and 6-month follow-ups include self-
reported 7-day-point prevalence of abstinence, nicotine
dependence (two-item heaviness of smoking index) [43],
number of cigarettes smoked, self-reported quit at-
tempts, and self-reported use of cessation aids.
Baseline characteristics
A number of client sociodemographic, smoking, and
clinical characteristics will be obtained, including age,
gender, marital status, Aboriginal or Torres Strait Is-
lander status, housing status, income and source of in-
come, education, postcode, smoking profile, and other
dependencies (alcohol and other drug use).
Cost-effectiveness
A cost-effectiveness analysis will be undertaken from the
perspective of healthcare providers and patients and will
compare the cost and effect from the organisational
change intervention to usual care. Costs will be stratified
according to whether they fall to the health provider or
patient. Health provider costs will include the cost of
materials used for education and promoting smoking
cessation (but not the research and development cost
for preparing the materials), clinical time, case worker
time, and the cost of resources committed to cessation
treatments. Patient out-of-pocket costs will also be
captured. These costs will be compared against the
study’s primary outcome measure: 7-day-point preva-
lence for smoking abstinence at 6-week follow-up. The
analysis will compare relative costs and outcomes in the
intervention and control centres and report the incre-
mental cost-effectiveness ratio (ICER). A sensitivity ana-
lysis will be conducted using variables with uncertain
values. The results will be considered in context of
strength of evidence, capacity of the intervention to re-
duce inequity, feasibility, sustainability, and potential for
other consequences.
Organisational system and process measures
A number of service variables will be measured to exam-
ine the relationship between the organisational change
intervention and different organisational structures.
Structural variables, which will be collected from the
head of each treatment service prior to randomisation
using an online survey, will include the number of new
patients each year, number of full-time and part-time
staff, type of treatment provision (e.g. opiate, alcohol or
combined) and governmental or non-governmental or-
ganisation. At 6-week follow-up, the clients will be asked
to indicate which components of the smoking cessation
intervention they were offered and/or received.
Sample size
Within each participating cluster, recruitment will occur
over a continuous 6-month period, with the aim of
recruiting 35 eligible clients per week (approaching 60
patients with 60 % consent [44, 45]) and giving a sample
size at baseline of approximately 450 per group. Al-
though strategies will be employed to reduce attrition
and maximise retention, based on previous research [46,
47] 40 % are expected to be lost to follow-up at 6 weeks,
thereby providing a sample of 270 participants per ex-
perimental arm (an average of 16–17 per treatment
centre). Assuming a 5 % significance level, 80 % power,
5 % smoking cessation in the control group for 7-day-
point prevalence, a design effect of 1.4 due to correlation
of observations within treatment services (an intra-class
correlation coefficient of approximately 0.025), and a
10 % allowance for unequal sized clusters, this sample
will allow detection of a 9 % difference in the 7-day-
point prevalence of abstinence between groups at
6 weeks. For the secondary outcomes, the study will
have 80 % power, with a 5 % significance level to detect
difference between groups in the 6 week self-reported 7-
day-point prevalence of abstinence, use of cessation aids
of approximately 9 %, and approximately one quarter of
a standard deviation in nicotine dependence and self-
reported number of quit attempts. We anticipate a 6-
month attrition of 50 %, with detectable differences of
Bonevski et al. Trials  (2016) 17:290 Page 6 of 9
10–11 % for binary outcomes and one third of a stand-
ard deviation for continuous outcomes.
Data analysis
Data will be stored in password-protected files with
group code concealed to those who conduct the analysis.
A full statistical analysis plan will be developed a priori.
Baseline characteristics will be presented for the inter-
vention and control groups. Logistic regression will be
used to compare the primary outcome and secondary
binary outcomes, linear regression will be used to com-
pare the heaviness of smoking index, and negative bino-
mial regression will be used to compare the number of
quit attempts and number of cigarettes smoked between
the two groups at each of the two follow-up times.
Mixed models will be used to adjust for correlation of
outcomes within treatment centres, and models will also
include stratification factors (state/territory, service type,
smoking policy). Main analyses will involve complete
cases, with sensitivity analyses conducted (1) using mul-
tiple imputation; and (2) treating missing outcomes as
smokers.
The final report will follow the CONSORT 2010
guidelines as well as its extension to cluster trials.
Discussion
This will be the first methodologically rigorous trial to
investigate the efficacy of an organisational change
smoking cessation intervention within the drug and al-
cohol treatment setting. The main expected outcomes
are improved health and a cost-effective sustainable or-
ganisational change intervention. Most smoking cessa-
tion interventions target the individual; this intervention
targets the treatment environment and system to pro-
duce quality improvement in healthcare provision. Or-
ganisational change interventions hold great potential as
cost-effective, sustainable strategies. A limitation of
individual-targeted approaches is limited reach. Changes
to systems reach larger numbers of people and changes
are maintained long-term. They also address the envir-
onmental context in which the behaviour occurs. Given
the study is a multi-state trial, the generalisability of the
study outcomes to the treatment centres across Australia
is increased. The intervention is also able to be modified
for other health behaviour or clinical outcomes of inter-
est (e.g. obesity, alcohol use).
The study is translational in nature with direct impli-
cations for health service provision in drug and alcohol
treatment centres, including publicly run and non-
governmentally run services. If cost-effective, the organ-
isational change intervention has potential for building
the capacity of addiction treatment centres to address
their clients smoking in the longer term, as well as the
potential transferability to other settings, reaching
disadvantaged smokers in prisons and mental health set-
tings and through social services. The intervention ad-
dresses existing inequity by targeting smoking cessation
amongst people in drug and alcohol treatment centres –
a cohort five times more likely than the general popula-
tion to smoke tobacco.
Trial status
The trial is ongoing.
Additional files
Additional file 1: Spirit checklist. A table specifying where any SPIRT
item has been addressed in the protocol manuscript. (PDF 129 kb)
Additional file 2: TNT Intervention Manual - FULL. An organisational
change intervention manual for smoking cessation in drug and alcohol
treatment centres. A comprehensive manual detailing the TNT
intervention strategies with reference to the background literature
supporting each of the intervention components and guiding theoretical
frameworks. (PDF 3047 kb)
Additional file 3: TNT Intervention Manual - BRIEF. TNT Project
Working Manual. A brief working document containing 1–2 page
user-friendly summaries of each of the eight components of the TNT
intervention with links to resources developed and/or provided as
part of the trial. (PDF 2612 kb)
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